Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) Coverage Initiated by Analysts at HC Wainwright

Equities research analysts at HC Wainwright initiated coverage on shares of Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) in a research note issued to investors on Wednesday, MarketBeat reports. The brokerage set a “buy” rating on the stock.

LABT has been the topic of several other research reports. Wall Street Zen upgraded Lakewood-Amedex Biotherapeutics from a “strong sell” rating to a “sell” rating in a research report on Sunday, September 6th. Weiss Ratings upgraded shares of Lakewood-Amedex Biotherapeutics from a “sell (e-)” rating to a “sell (e)” rating in a report on Friday, October 2nd. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold”.

Lakewood-Amedex Biotherapeutics Stock Performance

LABT stock traded down $0.00 during midday trading on Wednesday, hitting $0.29. 12,432,361 shares of the company’s stock were exchanged, compared to its average volume of 1,786,865. The stock’s fifty day moving average is $1.51. The company has a market cap of $675,450.00 and a P/E ratio of -0.06. Lakewood-Amedex Biotherapeutics has a one year low of $0.24 and a one year high of $98.20.

Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) last posted its earnings results on Friday, August 14th. The company reported ($2.75) earnings per share (EPS) for the quarter. On average, analysts predict that Lakewood-Amedex Biotherapeutics will post 4.96 earnings per share for the current fiscal year.

About Lakewood-Amedex Biotherapeutics

Lakewood-Amedex Biotherapeutics, Inc is a biotechnology company focused on the research and development of anti-infective therapies. Its work centers on developing treatments designed to address infections caused by bacteria and other pathogens.

The company’s activities are primarily directed toward advancing a pipeline of investigational therapeutic candidates rather than selling a broad portfolio of marketed products. Its development programs have focused on potential applications in human health, including treatments for localized and systemic infections.

Publicly available information about Lakewood-Amedex Biotherapeutics’ current product pipeline, commercial operations, geographic reach, and leadership is limited.